Skip to main content

Staphylococcal Infections

10
Pipeline Programs
7
Companies
11
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
6
0
2
0
0
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
583%
Small Molecule
117%
+ 8 programs with unclassified modality

On Market (1)

Approved therapies currently available

Pfizer
TYGACILApproved
tigecycline
Pfizer
Tetracycline-class Antibacterial [EPC]intravenous2005
85K Part D

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
5 programs
2
1
1
TigecyclinePhase 4Small Molecule1 trial
Staphylococcus aureus 4-antigen vaccinePhase 2Vaccine1 trial
SA4Ag vaccinePhase 1Vaccine1 trial
SA4Ag vaccine low dosePhase 1Vaccine1 trial
linezolidN/A1 trial
Active Trials
NCT00666276Completed1,004Est. Apr 2011
NCT02364596Completed100Est. Feb 2015
NCT01643941Completed284Est. Mar 2014
+2 more trials
Destiny Pharma
Destiny PharmaUK - Brighton
1 program
1
XF-73Phase 21 trial
Active Trials
NCT03915470Completed124Est. Mar 2021
MSD
MSDIreland - Ballydine
2 programs
2
V710Phase 11 trial
V710Phase 11 trial
Active Trials
NCT00303069Completed124Est. Jul 2006
NCT01324440Completed64Est. Oct 2007
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
2 programs
2
V710Phase 1
V710Phase 1
United Therapeutics
United TherapeuticsMD - Silver Spring
2 programs
NDV-3 investigational vaccinePHASE_1Vaccine1 trial
NDV-3 vaccine with alum IMPHASE_1Vaccine1 trial
Active Trials
NCT01273922Completed40Est. Dec 2011
NCT01447407Completed164Est. Dec 2012
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Modeling Host-Pathogen Interaction Using Lymphoid OrganoidsN/A1 trial
Active Trials
NCT06479837Recruiting500Est. Dec 2044
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
V710PHASE_1

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
PfizerTigecycline
Destiny PharmaXF-73
PfizerStaphylococcus aureus 4-antigen vaccine
PfizerSA4Ag vaccine
PfizerSA4Ag vaccine low dose
United TherapeuticsNDV-3 vaccine with alum IM
United TherapeuticsNDV-3 investigational vaccine
MSDV710
MSDV710
Allergy TherapeuticsModeling Host-Pathogen Interaction Using Lymphoid Organoids
Pfizerlinezolid

Clinical Trials (11)

Total enrollment: 2,550 patients across 11 trials

Open Label Non-comparative Clinical Trial of Tigecycline in Patients With Catheter Infection

Start: Jan 2007Est. completion: May 200810 patients
Phase 4Completed

Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection

Start: Aug 2019Est. completion: Mar 2021124 patients
Phase 2Completed
NCT02492958PfizerStaphylococcus aureus 4-antigen vaccine

SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults

Start: Jun 2015Est. completion: Sep 2016136 patients
Phase 2Completed
NCT02364596PfizerSA4Ag vaccine

Evaluation of a Single Vaccination With a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years

Start: Jan 2015Est. completion: Feb 2015100 patients
Phase 1Completed
NCT01643941PfizerSA4Ag vaccine low dose

Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years

Start: Aug 2012Est. completion: Mar 2014284 patients
Phase 1Completed
NCT01447407United TherapeuticsNDV-3 vaccine with alum IM

Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine

Start: Sep 2011Est. completion: Dec 2012164 patients
Phase 1Completed
NCT01273922United TherapeuticsNDV-3 investigational vaccine

Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida

Start: Jan 2011Est. completion: Dec 201140 patients
Phase 1Completed

Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002)

Start: Sep 2006Est. completion: Oct 200764 patients
Phase 1Completed

V710 First-In-Man (FIM) Study (V710-001)

Start: Nov 2005Est. completion: Jul 2006124 patients
Phase 1Completed
NCT06479837Allergy TherapeuticsModeling Host-Pathogen Interaction Using Lymphoid Organoids

Modeling Host-Pathogen Interaction Using Lymphoid Organoids

Start: Apr 2026Est. completion: Dec 2044500 patients
N/ARecruiting

Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan)

Start: Feb 2007Est. completion: Apr 20111,004 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 2,550 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.